ARTICLE | Clinical News
Kevetrin: Ph IIa started
February 16, 2017 8:22 PM UTC
Cellceutix began an open-label, U.S. Phase IIa trial to evaluate 250 and 350 mg/m2 IV Kevetrin thrice weekly for 3 weeks in about 10 patients....
BCIQ Company Profiles
Cellceutix began an open-label, U.S. Phase IIa trial to evaluate 250 and 350 mg/m2 IV Kevetrin thrice weekly for 3 weeks in about 10 patients....
BCIQ Company Profiles
BCIQ Company Profiles